Gilead’s subsidiary and Appia Bio signed a blood cancer cooperation agreement, with a transaction volume of US$875 million

On August 5, Gilead’s Kite and biotechnology company Appia Bio announced a cooperation license agreement to research and develop cell therapies for hematological malignancies

Constant natural killer T cells (iNKT) are a unique subgroup of T lymphocytes, which have the characteristics of both natural killer (NK) cells and T cells, and express T cell receptors (TCR) and NK cell surface markers

Appia Bio was established in 2020 and recently announced the completion of its Series A financing.

Dr.

"INKT cells already have a variety of tumor cell killing mechanisms through natural killer and T cell pathways

Dr.

Mert Aktar, Kite’s Vice President of Corporate Development and Strategy, said: "As a pioneer in cell therapy, Kite is firmly committed to developing next-generation cell therapies to treat cancer patients

According to the terms of the agreement, Appia Bio will be responsible for the preclinical and early clinical studies of two CAR-iNKT candidate products derived from hematopoietic stem cells, which are designed using chimeric antigen receptors provided by Kite

https:// href="https://" target="_blank" rel="noopener">https://